NASDAQ: HOOKHookipa Pharma Inc Stock
$1.23+0.02 (+1.65%)
Updated Mar 25, 2025
HOOK Price
$1.23
Fair Value Price
$3.10
Market Cap
$14.83M
52 Week Low
$1.11
52 Week High
$10.50
P/E
-0.35x
P/B
0.29x
P/S
0.55x
PEG
N/A
Dividend Yield
N/A
Revenue
$43.95M
Earnings
-$43.50M
Gross Margin
100%
Operating Margin
-99.23%
Profit Margin
-99%
Debt to Equity
0.61
Operating Cash Flow
-$77M
Beta
1.14
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
HOOK Overview
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine HOOK's potential to beat the market
- HOOK doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
HOOK
RankedUnranked of 481
RankedUnranked of 481
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.53 | A | |
| $135.25 | A | |
| $7.52 | A |
Be the first to know about important HOOK news, forecast changes, insider trades & much more!
HOOK News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how HOOK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HOOK ($1.23) is undervalued by 60.26% relative to our estimate of its Fair Value price of $3.10 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
HOOK ($1.23) is significantly undervalued by 60.26% relative to our estimate of its Fair Value price of $3.10 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
HOOK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more HOOK due diligence checks available for Premium users.
Valuation
HOOK fair value
Fair Value of HOOK stock based on Discounted Cash Flow (DCF)
Price
$1.23
Fair Value
$3.10
Undervalued by
60.26%
HOOK ($1.23) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
HOOK ($1.23) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
HOOK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
HOOK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.35x
Industry
-116.9x
Market
32.24x
HOOK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.29x
Industry
4.62x
HOOK is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
HOOK's financial health
Profit margin
Revenue
$1.4M
Net Income
-$25.0M
Profit Margin
-1,842.7%
HOOK's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
HOOK's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$82.5M
Liabilities
$31.3M
Debt to equity
0.61
HOOK's short-term assets ($80.67M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HOOK's short-term assets ($80.67M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HOOK's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
HOOK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$20.9M
Investing
-$2.0k
Financing
$0.0
HOOK's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
HOOK vs Biotech Stocks
Hookipa Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.